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Abstract The identification of mutations in the leucine-
rich repeat kinase 2 (LRRK2) gene as a cause of autosomal
dominant Parkinson’s disease (PD) was a major step for-
ward in the genetic dissection of this disorder. However,
what makes LRRK2 unique among the known PD-causing
genes is that a low-penetrance mutation, Gly2019Ser, is a
frequent determinant not only of familial, but also of spo-
radic PD in several populations from South Europe, North
Africa and Middle East. Moreover, a different polymorphic
variant, Gly2385Arg, is a frequent risk factor for PD among
Chinese and Japanese populations. Currently, the
Gly2019Ser and Gly2385Arg variants represent the most
relevant PD-causing mutation and risk allele, respectively,
linking the etiology of the familial and the sporadic forms of
this disease. Understanding how the dysfunction of LRRK2
protein leads to neurodegeneration might provide crucial
insights for unraveling the molecular mechanisms of PD
and for developing disease-modifying therapies.
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Introduction
Parkinson’s disease (PD) is the most common neurode-
generative movement disorder, and the second most com-
mon neurodegenerative disease after Alzheimer’s disease
(AD), with a prevalence of more than 1% after the age of
65 years [1]. The incidence of PD increases with age, and
the number of patients is expected to double by the year
2030, due to aging of the population, improved diagnosis
and prolonged survival, particularly in the developing
countries [2].
PD is clinically defined by adult-onset, progressive
parkinsonism (the combination of akinesia, resting tremor,
and muscular rigidity), which displays a beneficial re-
sponse to dopamine-replacement therapy [3]. In most pa-
tients, this clinical syndrome correlates with neuronal loss
and gliosis in the substantia nigra pars compacta and other
brain areas, and with formation of cytoplasmic inclusions
called Lewy bodies (LB) and Lewy neurites in the sur-
viving neurons.
The molecular mechanisms of PD remain mostly un-
known. Several lines of evidence, including biochemical
analysis, genomic and proteomic profiling of brain tissue,
cell and animal models, implicated mitochondrial defects,
oxidative stress, protein misfolding, proteasomal and
lysosomal abnormalities in the pathogenesis [4–12].
However, there are many reciprocal interactions between
these pathways, making it difficult to disentangle the pri-
mary and the secondary events. Moreover, the determi-
nants of the preferential vulnerability of the dopaminergic
system observed in PD remain unknown.
In most patients PD appears as a sporadic disorder. In
10–15% of cases the disease runs in families, but a Men-
delian inheritance is rarely evident from the pedigree
analysis. Yet, the ongoing identification of primary genetic
defects in patients with inherited forms of PD is rapidly
expanding the possible approaches to unravel the disease
pathogenesis [13].
Five genes are today considered as definitely implicated
in the etiology of PD. Mutations in the a-synuclein [14, 15]
and leucine-rich repeat kinase 2 (LRRK2) [16, 17] gene
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cause autosomal dominant forms whereas mutations in the
parkin [18], DJ-1 [19] and PINK1 (20) gene cause auto-
somal recessive forms of PD. LBs are found in the brain of
patients with a-synuclein mutations and in most of the
cases with LRRK2 mutations. On the other hand, LBs are
not present in most of the patients with parkin mutations,
while their occurrence in cases with DJ-1 or PINK1
mutations remains unknown.
The discovery that duplication and triplication of the
whole a-synuclein gene is also a cause of autosomal
dominant PD and of the related condition, dementia with
LBs, links directly the over-expression of wild-type a-
synuclein protein to the disease pathogenesis [15, 21, 22].
Moreover, common allelic variation in the a-synuclein
gene might increase the risk for the sporadic form of PD
[23]. A central role of a-synuclein in the pathogenesis of
PD is further supported by the fact that wild type a-syn-
uclein protein is the major component of the LBs and of
other neuronal and glial inclusions found in PD, dementia
with LBs, and multiple system atrophy, now collectively
termed ‘‘synucleinopathies’’ [24, 25].
LRRK2 mutations as a cause of PD
A genome-wide search for linkage in a large Japanese
pedigree with autosomal dominant, late-onset parkinson-
ism yielded the identification of a novel locus (PARK8) to
the peri-centromeric region of chromosome 12 [26].
Interestingly, autopsy study of four affected members of
this family revealed no LBs in the brain, a finding con-
sidered incompatible with a formal pathological diagnosis
of PD. However, linkage to the same chromosomal region
was later confirmed in two large families of European
ancestry, segregating parkinsonism associated with differ-
ent brain pathologies with or without LBs in different pa-
tients. This suggested PARK8 to be an important locus
with a pleomorphic pathology [27].
Using positional cloning strategies, in the year 2004,
LRRK2 was identified as the gene defective at the PARK8
locus [16, 17]. Soon thereafter, different groups identified a
single LRRK2 mutation (c.G6055A) leading to a
Gly2019Ser substitution in the encoded protein, which was
present in familial and sporadic PD with unprecedented
high frequency. A different mutation affecting the sub-
sequent amino acid, Ile2020Thr, was detected as the cause
of disease in the original Japanese PARK8 family [28]. The
following two years have seen an explosion of research
into the LRRK2 gene in PD and related disorders. Due to
the large size of its open reading frame (more than 7.5 kb
across 51 exons), a comprehensive screening of the entire
LRRK2 coding region has been rarely performed so far,
while in most studies large series of patients were screened
only for one or few known mutations.
The screening of the complete coding region of LRRK2
revealed mutations in ~10% of the PD cases with a family
history compatible with autosomal dominant inheritance
[29–32]; this figure by itself nominates LRRK2 as the most
common known genetic cause of the disease. However, a
note of caution is due here. For several mutations, co-
segregation studies have been very limited or lacking; large
series of ethnically matched controls have not always been
tested; and assays are not available yet to study the effects
of a given mutation on the function of the LRRK2 protein.
Due to all these reasons, the pathogenic nature remains
unclear for several of the LRRK2 mutations detected in PD
cases, and at least some of these (for example:
Arg1514Gln) might represent rare, benign variants [33,
34]. The uncertainties regarding the pathogenic nature of
the mutations found in the LRRK2 (as well as in any other
genes) are an important issue, which complicates the
transfer of the results of the genetic screening into the
clinics for diagnostic and genetic counseling purposes. To
date, only five LRRK2 mutations (Arg1441Cys, Arg1441-
Gly, Tyr1699Cys, Gly2019Ser, and Ile2020Thr) can be
considered as definitely disease causing, on the basis of a
clear co-segregation with PD in large pedigrees and
absence in large series of controls (Fig. 1).
Another very important aspect is the wide pathological
spectrum associated with LRRK2 mutations (~30 cases came
to autopsy so far) [35]. Dopaminergic neuronal cell loss and
gliosis in the substantia nigra are the common features in the
patients carrying LRRK2 mutations [17]. In addition, clas-
sical LBs were found in the majority of cases, but in few,
there was absence of inclusions, or only tau-positive or
ubiquitin-positive inclusions were detected [31, 36–42].
These observations are based on a limited number of brains,
and further studies are warranted. However, the pathologic
pleomorphism seems a common theme for the different
LRRK2 mutations, at least for Arg1441Cys, Tyr1699Cys,
and Gly2019Ser, suggesting that our pathological defini-
tion of PD and related diseases has to be revised.
The Gly2019Ser story
Gly2019Ser is particularly important among the PD-caus-
ing mutations in LRRK2. This mutation was identified by
several groups as a common cause of the disease, being
detected initially in ~5–6% of large cohorts of familial PD
in Europe and US, and in ~1–2% of sporadic PD from UK
[43–47]. It is now clear that the frequency of Gly2019Ser
in PD varies greatly across populations [48]. The results of
the different studies are not easily comparable because of
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the different sample size, different methods for patient
ascertainment, different definitions of ‘‘familial’’ versus
‘‘sporadic’’ disease, and different genotyping techniques,
and much more work remains therefore ahead. The
Gly2019Ser mutation has not been identified in three large
series of Chinese patients [49–51], though it was rarely
found in Indian [52] and Japanese patients [53, 54]. Studies
in large referral series from the US population estimated a
mutation frequency of up to ~3% in familial and ~0.7% in
sporadic cases, respectively [55, 56]. This mutation seems
present at lower frequency in patients from Northern Eur-
ope [57–61], than in those from Southern Europe such as
Italy (~5% of familial and ~1% of sporadic cases) [62, 63],
Spain and Portugal (up to ~6–18% of familial and ~3–6%
of sporadic cases) [64–67](Ferreira et al. unpublished data).
However, an extremely high prevalence is found among
Arab patients from North Africa (~37% of familial and
~41% of sporadic cases) and among Ashkenazi Jewish
patients (~29% of familial and ~13% of sporadic cases)
[68, 69]. The prevalence of this mutation remains to be
investigated in other large populations, such as those from
Brazil, and other countries of Latin America.
Gly2019Ser represents clearly the first common patho-
genic mutation identified in PD, establishing for the first
time the proof-of-principle for a genetic determinant fre-
quently involved in the classical, late-onset, sporadic forms
of this disease.
Most of the patients carrying this mutation and living in
disparate countries in Europe and America, share a com-
mon, very old founder haplotype [46, 62, 70], which likely
originated from North Africa or Middle East ~2,000 years
ago or earlier [71]. A second haplotype has been detected
in a few patients of European ancestry [71], while a third
haplotype was found in Japanese patients [54]. The
occurrence of Gly2019Ser in at least three different hapl-
otypes suggests either an extremely old founder, or a
mutational hot spot. Another hot spot might be represented
by LRRK2 codon 1441, where three different mutations are
known to occur (Arg1441Cys, Arg1441Gly, Arg1441His)
[17, 29, 32, 72–74].
Mapping and cloning of genes for dominantly inherited
diseases often relies on families with an exceptionally high
number of affected individuals. This leads to an inherent
ascertainment bias, and an overestimation of the mutation
penetrance. However, after a causative mutation is identi-
fied, more accurate values of penetrance can be estimated
in unselected, consecutive series of patients, ideally from
population-based studies. This approach might yield con-
siderably lower figures of penetrance. In the case of
PARK8, a reduced penetrance of the underlying mutation
was already suggested in the initial linkage study [26], and
confirmed after the identification of the LRRK2 gene. Re-
cent estimates of the lifetime penetrance of the Gly2019Ser
mutation in large, hospital-based but otherwise unselected
series of PD patients (US Jewish, US non-Jewish, and
Italians) yielded values of ~24–33% [56, 69, 75]. Yet, the
penetrance might be different in other populations and
additional studies are therefore warranted before
Gly2019Ser testing is used for genetic counseling. Such a
low penetrance explains the high Gly2019Ser prevalence
among patients with sporadic PD, and its rare occurrence in
controls (~1%), particularly among the populations with
the highest mutation frequencies such as Arabs and Ash-
kenazi Jews [68, 69].
Due to a lower frequency, the penetrance of other
LRRK2 mutations is more difficult to estimate accurately,
but reduced values are also suggested by analysis of ped-
igrees segregating the second most recurrent LRRK2
mutation, Arg1441Cys [62, 76].
The clinical phenotype of Gly2019Ser-positive patients
appears very similar, or indistinguishable from that of the
classical form of PD, but a wide range of onset age is
evident [45, 55, 56, 62, 63, 77]. Several patients, mostly
from Tunisia and Algeria, were identified who carry the
Gly2019Ser mutation in homozygous state [78–80]. This is
likely due to the high prevalence of the mutation, and the
high frequency of consanguineous marriages in those
populations. Homozygous carriers of this mutation seem
not to develop PD at an earlier age, nor to have a more
severe disease, or a more aggressive course, compared to
Fig. 1 Schematic
representation of the human
LRRK2 protein. The known
functional domains are shown,
the catalytic domains in black
and the protein-protein
interaction domains in grey.
Five definitely PD-causing
mutations and one PD-
associated polymorphism are
also displayed
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the heterozygous carriers [80]. However, it is difficult to
draw firm conclusions, as the clinical spectrum associated
in heterozygous mutation carriers is also very broad.
Interestingly, the penetrance might be higher in homozy-
gous carriers [79], arguing for the presence of a mutation
dosage effect. The low penetrance and variable phenotypic
expressivity of the mutation suggest the existence of fur-
ther important modifiers, which might include other genetic
as well as non-genetic factors. Their identification is an
important area of the current research.
Gly2385Arg: a common risk allele for PD in Asia
At the beginning of the year 2006, we found that a different
LRRK2 variant, Gly2385Arg, is a polymorphism in the Han
Chinese population from Taiwan (frequency of heterozy-
gous carriers ~5% among controls), and it is significantly
more frequent (~10%) among PD cases [81]. We therefore
proposed that Gly2385Arg is a common risk factor for PD
in the Han population. Interestingly, this variant was ini-
tially detected in a single, small PD family from Taiwan
[29], but it has not been observed so far among whites [30–
32], and it appears therefore specific for the Asian popu-
lation. The association between Gly2385Arg and PD has
now been confirmed in at least four independent replication
studies, involving more than 2000 individuals (three tar-
geting the Chinese, and one the Japanese population) [82–
85] (Table 1).
Using the observed frequency of the Gly2385Arg
genotype among controls and the observed value of odds
ratio as estimates of the risk genotype frequency in the
general population, and of the relative risk, respectively,
one can calculate a population attributable risk of ~4% for
the Gly2385Arg heterozygous genotype in the Han Chinese
population [82]. Cross-sectional case control studies are
prone to several biases, including survival bias. It is
therefore crucial to replicate this finding also in large
prospective studies. However, the replication of the asso-
ciation in the same direction-of-effect and with similar
effect size (odds ratio ~2.5 in most studies) in four inde-
pendent, large samples of different geographic and ethnic
origin (Table 1), and the potential functional effects of this
missense, non-conservative variant, all strongly support the
contention that this represents a real, causal association.
Gly2385Arg might be the first identified genetic risk factor
for the common PD form in the Asian population, and the
most frequent genetic determinant of PD worldwide, also
considering the large and expanding size of the Chinese
population (projected number of ~5 millions patients by the
year 2030) [2].
As observed for the Gly2019Ser carriers, the clinical
spectrum in PD patients who carry the Gly2385Arg variant
is very broad and indistinguishable from that of the cases
who do not carry it.
The Gly2385Arg variant is located at the surface of the
C-terminal WD40 domain of the LRRK2 protein, where it
introduces an additional, net positive electric charge.
WD40 domains are involved in protein–protein interac-
tions, and they might be important for the formation of
complexes between LRRK2 and other proteins, or for the
LRRK2 dimerization. It is possible that the Gly2385Arg
variant increases the risk of PD by affecting these bio-
chemical properties of the LRRK2 protein.
The LRRK2 protein
LRRK2 mutation causes a disease that most closely
resembles the common forms of PD. The LRRK2 protein is
likely to be a very important player in the pathogenesis of
PD in general, and the pharmacological manipulation of
the LRRK2 activity might become a future important
therapeutic strategy. It is therefore urgent to unravel the
biology of the LRRK2 protein, and how its mutation leads
to neurodegeneration, but very little is known about these
crucial aspects.
LRRK2 encodes a 2,527 amino acids protein of unknown
function, belonging to the ‘‘ROCO’’ group within the Ras/
GTPase superfamily [86], and characterized by the pres-
ence of several conserved domains: a Roc (Ras in complex
proteins) and a COR (C-terminal of Roc) domain, together
with a leucine-rich repeat region, a WD40 domain, two
ankyrin-like motifs, and a protein kinase catalytic domain
(Fig. 1). Review of the ROCO family members reveals
involvement in diverse cellular processes (regulation of
Table 1 Allelic association studies of the Gly2385Arg variant as risk factor for PD
Study Target population Cases Controls OR P Ref
Di Fonzo et al. Chinese (Han), Taiwan 608 373 2.24 0.012 [81]
Tan et al. Chinese, Singapore 494 495 2.67 0.002 [82]
Fung et al. Chinese (Han), Taiwan 305 176 16.99 0.0002 [83]
Farrer et al. Chinese, Taiwan 410 335 2.24 0.014 [84]
Funayama et al. Japanese 463 457 2.51 0.0002 [85]
Neurochem Res (2007) 32:1700–1708 1703
123
cell polarity, chemotaxis, cytokinesis, cytoskeletal rear-
rangements, and programmed cell death), making impos-
sible to predict the function of human LRRK2 on the basis
of homology (reviewed in [86, 87]).
Initial studies suggest that the LRRK2 mRNA [88–91]
and the LRRK2 protein [39, 88, 92, 93] are broadly ex-
pressed throughout the brain, including nigral neurons, and
that the LRRK2 protein shows a cytosolic localization,
perhaps in association with membranous structures [93].
There is also evidence that the LRRK2 protein regulates
the length and branching of neurites and this function
might be impaired by PD-causing mutations [94].
LRRK2 immunoreactivity has been reported in some
LBs from PD brains [92, 95]. However, most of the cur-
rently available LRRK2 antibodies lack optimal sensitivity
and specificity, and further investigations are definitely
warranted.
One of the two predicted catalytic domains (GTPase and
kinase) represents likely the output activity of LRRK2.
Small GTPases (Rho, Rac, Cdc42) usually act upstream of
protein kinases. By analogy, the GTPase domain might
regulate the LRRK2 kinase domain via intramolecular
signaling. Whether the LRRK2 kinase activity is required
for the phosphorylation of target proteins, or whether it
plays an auto-regulatory role, is currently unclear. The PD-
causing mutations replace highly conserved residues, but,
in addition, the Glycine2019 residue is remarkable because
it is conserved in all human kinase domains. These muta-
tions could destabilize the kinase domain, resulting in loss-
of-function of the kinase activity, and suggesting haploin-
sufficiency as disease mechanism. Another possibility is
that Gly2019Ser and other mutations enhance the kinase
activity. Of note, the three known PD-causing mutations in
the kinase domain (Ile2012Thr, Gly2019Ser, and
Ile2020Thr) all introduce novel potential auto-phosphory-
lation sites, and similar mutations in the activation segment
of other kinases induce hyper-activity [96]. This mecha-
nism would confer a gain of function to the mutant protein,
fitting with the dominant pattern of inheritance seen in
families with LRRK2 mutations.
Over-expressing the human wild-type LRRK2 protein in
different cell systems is associated with formation of cyto-
plasmic inclusions [92, 97]. Moreover, LRRK2 shows pro-
tein kinase activity in vitro toward generic substrates and is
capable of auto-phosphorylation [92, 98, 99]. Importantly,
some of the PD-causing mutations (particularly those located
in the kinase domain) appear to enhance the LRRK2 kinase
activity in vitro, as well as the inclusion formation, and they
induce cell toxicity and ultimately, cell death [92, 97–99].
LRRK2 also displays GTP-binding properties in vitro, and
GTP binding seems required for the kinase domain of
LRRK2 to be in an active state [100–102]. However, LRRK2
seems devoid of intrinsic GTPase activity, suggesting the
involvement of other interacting proteins, such as GTPase
activating proteins (GAPs), and guanine nucleotide ex-
change factors (GEFs) [100–102]. Here, the caveat is that all
these findings need validation using in vivo models, and after
the (currently unknown) physiological interactors and sub-
strates of the LRRK2 protein are identified. A study focusing
on the homologue LRRK1 protein came to the opposite
conclusion that the LRRK1 kinase activity might be de-
creased by amino acid substitutions corresponding to the PD-
causing mutations in LRRK2 [103]. Much more work re-
mains ahead in order to understand the biology and pathol-
ogy of this complex, fascinating protein.
Conclusions
The discovery of LRRK2 mutations in PD led to a turning
point in the field. For the first time, gene mutations, and
particularly the low-penetrance Gly2019Ser mutation
prove to be a frequent genetic determinant of familial and
sporadic forms of this disease in several populations; the
Gly2385Arg polymorphic variant is a common risk factor
for PD in Asia. In both cases, the associated clinical phe-
notype is indistinguishable from the classical, late-onset
PD, and brain study reveals a broad pathological spectrum,
which includes in most cases the typical LB pathology.
Importantly, this frequent low-penetrance mutation and the
frequent risk allele provide etiological links between the
familial and the sporadic forms of PD.
Elucidating the function of the LRRK2 protein and how
LRRK2 dysfunction leads to neurodegeneration might
provide crucial insights for understanding the molecular
mechanisms of PD and yield novel avenues to the devel-
opment of a cure. The pharmacological modulation of one
or both catalytic LRRK2 activities could become innova-
tive, important therapeutic strategy for all patients with PD
and related neurodegenerative diseases.
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